The market is inefficient.
Hype and herd mentality swamp common sense at times.
Why didn't the FDA state that the sample size was two small at the initial meeting or at the first PMA filing or at the second PMA filing?
Why now drag it out 10 months before asking for more data?
Isn't there an Appeal process?
I recall that Vanda Pharma filed an Appeal and the initial decision was reversed and the drug was approved on Appeal.
GTHP produces a biophotonic cervical cancer scan.
It's noninvasive, more accurate tan pap smears and produces instant test results.
GTHP recently shipped its first units to China (see the PR).
There are over 390M women in China between the ages 25 and 64 in need of Hep C testing.
Orders were received from Turkey and Indonesia too.
GTHP is awaiting FDA approval in the US - the stock price should triple on the announcement which is expected any day.
The Hep C market is huge - over 60M pap smear tests are taken annually in the US.
At a market cap of only $20M and FDA approval expected within days - GTHP could be the stock of the year.
We are talking about investing. Put your money behind successful companies.
GILD has 19 approved drugs vs none for INO, and they were founded after INO
Which is the better investment?
The landscape is littered with failed companies. You want to Invest in them and hope that somehow the failure will be transformed into success. Is that your strategy to investing?
Failed technology from Inovio under a nonexclusive license won't help anyone.
The reverse split won't help you.
Never buy reverse split stocks. Successful quality stocks have forward splits.
$20M market cap vs $50M
100M shares outstanding vs 270M
Awaiting FDA approval vs years away from approval
Approved internationally vs no approvals
Competent CEO from GE Diagnostics and Abbott vs a sociology major CEO
Hey, it can't be worse than ONCS.
Buy undervalued stocks:
GTHP is at $20M with FDA approval expected this month for the huge Hep C market.
Over 60M pap smear tests are taken annually in the US.
GTHP's biophotonic cervical cancer scan is noninvasive, more accurate and produces instant test results.
It's already approved in EU, Asia, Canada, Mexico.
International sales are ramping up - see the recent news on orders from China, Indonesia, Kenya.....
The new CEO was formerly with GE Diagnostics and Abbott Healthcare.
Intellectual property: GTHP has dozens of biophotonics patents, an approved product in EU, Canada, Mexico, Asia and awaiting FDA approval with a market cap of $20M.
EXAS with inferior technology has a market cap of $2 billion.
Undervaluations and TulipMania overvalutions can be found in the market.
FDA approval ..... exercise of options ....... partnership?
Most biotechs are constantly in need of cash. That doesn't prevent $billion valuations.
So hiring someone to do a crime absolves you?
is that your judicial theory?
What law school did you graduate from?
This is one of the most egregious Pump & Dump schemes. Insiders caused intentional severe financial losses on their own shareholders so that they could fill their pockets. They were caught red handed. And you are proposing what?